Ovarian Cancer Immunotherapy and Personalized Medicine

被引：254
作者：
Morand, Susan [1 ]
Devanaboyina, Monika [1 ]
Staats, Hannah [1 ]
Stanbery, Laura [2 ]
Nemunaitis, John [2 ]
机构：
[1] Univ Toledo, Dept Med, Toledo, OH 43614 USA
[2] Gradalis Inc, Carrollton, TX 75006 USA
来源：
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | 2021年 / 22卷 / 12期
关键词：
ovarian cancer; immunotherapy; biomarker; TUMOR-INFILTRATING LYMPHOCYTES; CELL LUNG-CANCER; HOMOLOGOUS RECOMBINATION DEFICIENCY; PLATINUM-RESISTANT OVARIAN; GYNECOLOGIC-ONCOLOGY-GROUP; INTRAEPITHELIAL T-CELLS; FOLATE BINDING-PROTEIN; PHASE-III TRIAL; MUTATIONAL BURDEN; PD-1; BLOCKADE;
D O I：
10.3390/ijms22126532
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
Ovarian cancer response to immunotherapy is limited; however, the evaluation of sensitive/resistant target treatment subpopulations based on stratification by tumor biomarkers may improve the predictiveness of response to immunotherapy. These markers include tumor mutation burden, PD-L1, tumor-infiltrating lymphocytes, homologous recombination deficiency, and neoantigen intratumoral heterogeneity. Future directions in the treatment of ovarian cancer include the utilization of these biomarkers to select ideal candidates. This paper reviews the role of immunotherapy in ovarian cancer as well as novel therapeutics and study designs involving tumor biomarkers that increase the likelihood of success with immunotherapy in ovarian cancer.
引用
收藏
页数：19
相关论文
共 161 条
  • [1] Intraepithelial T Cells and Tumor Proliferation
    Adams, Sarah F.
    Levine, Douglas A.
    Cadungog, Mark G.
    Hammond, Rachel
    Facciabene, Andrea
    Olvera, Narciso
    Rubin, Stephen C.
    Boyd, Jeff
    Gimotty, Phyllis A.
    Coukos, George
    [J]. CANCER, 2009, 115 (13) : 2891 - 2902
  • [2] PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome
    Alsaab, Hashem O.
    Sau, Samaresh
    Alzhrani, Rami
    Tatiparti, Katyayani
    Bhise, Ketki
    Kashaw, Sushil K.
    Iyer, Arun K.
    [J]. FRONTIERS IN PHARMACOLOGY, 2017, 8
  • [3] Tumor infiltrating lymphocyte therapy for ovarian cancer and renal cell carcinoma
    Andersen, Rikke
    Donia, Marco
    Westergaard, Marie Christine Wulff
    Pedersen, Magnus
    Hansen, Morten
    Svane, Inge Marie
    [J]. HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2015, 11 (12) : 2790 - 2795
  • [4] Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer
    Andre, T.
    Shiu, K-K
    Kim, T. W.
    Jensen, B., V
    Jensen, L. H.
    Punt, C.
    Smith, D.
    Garcia-Carbonero, R.
    Benavides, M.
    Gibbs, P.
    de la Fouchardiere, C.
    Rivera, F.
    Elez, E.
    Bendell, J.
    Le, D. T.
    Yoshino, T.
    Van Cutsem, E.
    Yang, P.
    Farooqui, M. Z. H.
    Marinello, P.
    Diaz, L. A., Jr.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (23) : 2207 - 2218
  • [5] PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
    Ansell, Stephen M.
    Lesokhin, Alexander M.
    Borrello, Ivan
    Halwani, Ahmad
    Scott, Emma C.
    Gutierrez, Martin
    Schuster, Stephen J.
    Millenson, Michael M.
    Cattry, Deepika
    Freeman, Gordon J.
    Rodig, Scott J.
    Chapuy, Bjoern
    Ligon, Azra H.
    Zhu, Lili
    Grosso, Joseph F.
    Kim, Su Young
    Timmerman, John M.
    Shipp, Margaret A.
    Armand, Philippe
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (04) : 311 - 319
  • [6] AOKI Y, 1991, CANCER RES, V51, P1934
  • [7] The combined presence of CD20+B cells and PD-L1+tumor-infiltrating lymphocytes in inflammatory breast cancer is prognostic of improved patient outcome
    Arias-Pulido, H.
    Cimino-Mathews, A.
    Chaher, N.
    Qualls, C.
    Joste, N.
    Colpaert, C.
    Marotti, J. D.
    Foisey, M.
    Prossnitz, E. R.
    Emens, L. A.
    Fiering, S.
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2018, 171 (02) : 273 - 282
  • [8] The folate receptor as a rational therapeutic target for personalized cancer treatment
    Assaraf, Yehuda G.
    Leamon, Christopher P.
    Reddy, Joseph A.
    [J]. DRUG RESISTANCE UPDATES, 2014, 17 (4-6) : 89 - 95
  • [9] Ten-Year Relative Survival for Epithelial Ovarian Cancer
    Baldwin, Lauren A.
    Huang, Bin
    Miller, Rachel W.
    Tucker, Thomas
    Goodrich, Scott T.
    Podzielinski, Iwona
    DeSimone, Christopher P.
    Ueland, Fred R.
    van Nagell, John R.
    Seamon, Leigh G.
    [J]. OBSTETRICS AND GYNECOLOGY, 2012, 120 (03) : 612 - 618
  • [10] Tumor antigens heterogeneity and immune response-targeting neoantigens in breast cancer
    Benvenuto, Monica
    Focaccetti, Chiara
    Izzi, Valerio
    Masuelli, Laura
    Modesti, Andrea
    Bei, Roberto
    [J]. SEMINARS IN CANCER BIOLOGY, 2021, 72 : 65 - 75
12345678910